An important topic of discussion amongst the extracellular vesicle (EV) research field is which genetic materials are considered true constituents of EV cargo. What were once regarded as non‐EV components have now evolved to be potentially essential to EV composition, serving as key mediators in communication. Researchers continue to pursue varying methods for the isolation of EVs with the desired content. However, the desired content depends on the source and the requirements of the intended downstream use of EVs. Different isolation methods can modify EV cargo, impacting functional EV‐induced effects and analysis of EV contents. Ensuring that any result produced is truly representative of EVs and not of co‐isolated materials is imperative. Here, we describe a side‐by‐side comparison of the outcomes of EV isolation from plasma of healthy individuals, using size exclusion chromatography and an ultrafast filtration system. Characterisation of EVs was performed by particle (nanoparticle tracking analysis), protein (Bradford assay) and lipid (sulfo‐phospho‐vanillin assay) quantification, morphology visualisation (transmission electron microscopy), microRNA expression (miRNA sequencing) and assessment of protein absence or presence (traditional and capillary‐based western blot analyses, ELISA and mass spectrometry). To our surprise, the isolation methods employed identified significant differences in the protein abundance and composition of the resulting EVs. SEC isolated plasma EVs with high abundance of EV transmembrane and cytosolic markers, as well as corona‐related complement, fibrinogen and extracellular matrix proteins. However, this was accompanied by high quantities of non‐EV immunoglobulins. In contrast, UFF isolated plasma EVs with high abundance of EV integrins and corona‐related complement proteins, albeit with high lipoprotein abundance. Each isolation approach produces EVs with different biomolecular properties, which might provide specific advantages and disadvantages, depending on the intended use of EVs. Therefore, isolation methods need to be tested intensively and selected carefully for downstream applications.
Background: Head and neck squamous cell carcinoma (HNSCC) remains a major global health challenge due to the lack of effective and non-invasive diagnostic tools, often resulting in late-stage detection of cancer. Small extracellular vesicles (sEVs) have emerged as promising biomarkers for early cancer detection and disease monitoring due to their omnipresence and stability in bodily fluids, such as blood plasma. In addition, cancer-derived sEVs specifically carry cargo reflective of oncogene-derived molecular alterations. In summary, these characteristics position sEVs as a potential platform for non-invasive testing of HNSCC. Methods: Plasma-derived sEVs from HNSCC patients (n = 71) and benign subjects (n = 25) were isolated using size exclusion chromatography. Proteomic profiling via liquid chromatography-tandem mass spectrometry identified potential candidate biomarkers, followed by ELISA validation. Results: Proteomic analyses revealed a significant enrichment of multiple proteins in HNSCC-derived sEVs compared to sEVs derived from non-cancer individuals. The von Willebrand factor (vWF) was significantly higher in HNSCC patient-derived sEVs compared to those derived from benign individuals. A validation cohort confirmed that sEV-associated vWF (sEV-vWF) effectively distinguished HNSCC patients from benign subjects, demonstrating strong diagnostic performance, specifically in laryngeal HNSCC (AUC = 0.82) and oropharyngeal HNSCC (AUC = 0.96) patient cohorts. Moreover, postoperative reductions and recurrence-associated increases in sEV-vWF levels corresponded with clinical outcomes, indicating its potential as a dynamic disease indicator. Conclusions: These findings highlight sEV-vWF as a novel and non-invasive biomarker with potential applications in early detection and real-time monitoring of HNSCC, supporting advancement toward precision liquid biopsy strategies in head and neck oncology.
Melanoma is a highly immunogenic cancer, and immunotherapy is the first-line treatment for patients with advanced disease. However, CD155 overexpression in melanoma has been associated with resistance to immunotherapy. Whether CD155 can be transferred from tumour cells via extracellular vesicles (EVs), and how this transfer affects immune responses in melanoma, remains unclear. To investigate melanoma cell transfer of CD155 in vivo, B16F10-WT and B16F10-CD155KO melanoma cells were subcutaneously injected into CD155−/− mice. We show that CD155 is transferred from melanoma cells to several immune cell populations infiltrating the tumour, at least partly through EV secretion and uptake. DNAM-1 expression was significantly reduced on natural killer (NK) cells in B16F10-WT tumours compared with B16F10-CD155KO tumours. We also found that CD155 was enclosed and enriched in different melanoma EV subtypes. Finally, incubation of NK cells with CD155+ melanoma EVs increased cellular CD155 levels and led to downregulation of DNAM-1. In summary, melanoma-derived CD155 is enriched in melanoma EVs and transferred to immune cells, especially NK cells. Moreover, cancer-derived CD155+ EVs increase CD155 expression on NK cells and are associated with reduced DNAM-1 expression.